Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

Future Oncology

Volumn 11, Issue 3, 2015, Pages 421-429

  De Marinis, Filippo ^a,b   Vergnenegre, Alain ^c   Passaro, Antonio ^a,b   Dubos Arvis, Catherine ^d   Carcereny, Enric ^e   Drozdowskyj, Ana ^f   Zeaiter, Ali ^g   Perez Moreno, Pablo ^g   Rosell, Rafael ^e  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Oncological Pulmonary 1st Unit   (Italy)

^c Hopital du Cluzeau   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f Pivotal SL ^*  (Spain)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

EGFR; erlotinib; non small cell lung cancer; rash; safety

Indexed keywords

ANTIBIOTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; STEROID; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; EXANTHEMA; GENETICS; INCIDENCE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MORTALITY; MULTICENTER STUDY; MUTATION; PHASE 3 CLINICAL TRIAL; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; EXANTHEMA; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923093517     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.269     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Schiller JH, Harrington D, Belani CF et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002).
3. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006).
4. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl. 1), S24-S31 (2009).
5. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 358, 1160-1174 (2008).
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
7. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12, 735-742 (2011).
8. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13, 239-246 (2012).
9. Mok TS, Wu Y-L, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
10. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327-3334 (2013).
11. Qi WX, Shen Z, Lin F et al. Comparison of the efficacy and safety of EGFR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac. J. Cancer Prev. 13, 5177-5182 (2012).
12. Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr. Oncol. 18, 126-138 (2011).
13. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6, 803-812 (2006).
14. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 24, 3831-3837 (2006).
15. Chen G, Feng J, Zhou C et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a Phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann. Oncol. 24, 1615-1622 (2013).
16. Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12, 610-621 (2007).
17. Passaro A, Di Maio M, del Signore E et al. Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. Clin. Lung Cancer 15, 307-12 (2014).
18. Costa C, Molina-Vila M, Drozdowskyj A et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized Phase III EURTAC trial. Clin. Cancer Res.20(7), 2001-2010 (2014).
19. Lacouture M, Anaduat M, Bensadoun R-J et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19, 1079-1095 (2011).
20. Lacouture M, Schadendorf D, Chu C et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Exp. Rev. Anticancer Ther. 13, 721-728 (2013).
21. Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J. Am. Acad. Dermatol. 69, 463-72 (2013).
22. Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol. Res. Pract. 2014, 734249 (2014).
23. Lacouture ME, Mitchell EP, Piperdi B et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a Phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 1351-1357 (2010).
24. Deplanque G, Chavaillon J, Vergnenegre A et al. CYTAR: a randomized clinical trial evaluating the preventative effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J. Clin. Oncol. 28(Suppl. 15), 9019 (2010).
25. Gerber PA, Meller S, Eames T et al. Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. Eur. J. Med. Res. 17, 4 (2012).
26. Scope A, Agero AL, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J. Clin. Oncol. 25, 5390-5396 (2007).